Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolle...

Descripción completa

Detalles Bibliográficos
Autores: Feliú Batlle, Jaime, Safont, María José, Salud, Antonieta T., Losa, Ferrán C., García-Girón, Carlos, Bosch, Carles J A, Escudero, Pilar, López Manzanera, Rafael, Madroñal, C., Bolaños, Margarita, Gil, Mireia, Llombart, Antonio C., Castro Carpeño, Francisco Javier de, González Barón, Manuel
Tipo de recurso: artículo
Fecha de publicación:2010
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/662397
Acceso en línea:http://hdl.handle.net/10486/662397
https://dx.doi.org/10.1038/sj.bjc.6605663
Access Level:acceso abierto
Palabra clave:Aged
Bevacizumab
Capecitabine
Colorectal neoplasms
Neoplasm metastasis
Medicina
id ES_950b2efc8c8d10c122db32edcb2b28ee
oai_identifier_str oai:repositorio.uam.es:10486/662397
network_acronym_str ES
network_name_str España
repository_id_str
spelling Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancerFeliú Batlle, JaimeSafont, María JoséSalud, Antonieta T.Losa, Ferrán C.García-Girón, CarlosBosch, Carles J AEscudero, PilarLópez Manzanera, RafaelMadroñal, C.Bolaños, MargaritaGil, MireiaLlombart, Antonio C.Castro Carpeño, Francisco Javier deGonzález Barón, ManuelAgedBevacizumabCapecitabineColorectal neoplasmsNeoplasm metastasisMedicinaBACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study. METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of 30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks. RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and 18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome (19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of previous reports in elderly patients. CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be unsuitable for receiving polychemotherapy.This study was supported by Hoffmann-La Roche, Nutley, NJ, USA.Nature Publishing GroupDepartamento de MedicinaFacultad de Medicina20102010-05-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10486/662397https://dx.doi.org/10.1038/sj.bjc.6605663reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.uam.es:10486/6623972026-06-23T12:46:27Z
dc.title.none.fl_str_mv Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
title Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
spellingShingle Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
Feliú Batlle, Jaime
Aged
Bevacizumab
Capecitabine
Colorectal neoplasms
Neoplasm metastasis
Medicina
title_short Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
title_full Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
title_fullStr Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
title_full_unstemmed Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
title_sort Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
dc.creator.none.fl_str_mv Feliú Batlle, Jaime
Safont, María José
Salud, Antonieta T.
Losa, Ferrán C.
García-Girón, Carlos
Bosch, Carles J A
Escudero, Pilar
López Manzanera, Rafael
Madroñal, C.
Bolaños, Margarita
Gil, Mireia
Llombart, Antonio C.
Castro Carpeño, Francisco Javier de
González Barón, Manuel
author Feliú Batlle, Jaime
author_facet Feliú Batlle, Jaime
Safont, María José
Salud, Antonieta T.
Losa, Ferrán C.
García-Girón, Carlos
Bosch, Carles J A
Escudero, Pilar
López Manzanera, Rafael
Madroñal, C.
Bolaños, Margarita
Gil, Mireia
Llombart, Antonio C.
Castro Carpeño, Francisco Javier de
González Barón, Manuel
author_role author
author2 Safont, María José
Salud, Antonieta T.
Losa, Ferrán C.
García-Girón, Carlos
Bosch, Carles J A
Escudero, Pilar
López Manzanera, Rafael
Madroñal, C.
Bolaños, Margarita
Gil, Mireia
Llombart, Antonio C.
Castro Carpeño, Francisco Javier de
González Barón, Manuel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Departamento de Medicina
Facultad de Medicina
dc.subject.none.fl_str_mv Aged
Bevacizumab
Capecitabine
Colorectal neoplasms
Neoplasm metastasis
Medicina
topic Aged
Bevacizumab
Capecitabine
Colorectal neoplasms
Neoplasm metastasis
Medicina
description BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study. METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of 30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks. RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and 18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome (19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of previous reports in elderly patients. CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be unsuitable for receiving polychemotherapy.
publishDate 2010
dc.date.none.fl_str_mv 2010
2010-05-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10486/662397
https://dx.doi.org/10.1038/sj.bjc.6605663
url http://hdl.handle.net/10486/662397
https://dx.doi.org/10.1038/sj.bjc.6605663
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413759176409088
score 15.300724

Similares en LA Referencia